Access Worries Persist after ICER’s Arthritis Report, Meeting

A drug pricing watchdog group had its final say Friday on targeted arthritis treatments – and it may not be good news for patients.
A drug pricing watchdog group had its final say Friday on targeted arthritis treatments – and it may not be good news for patients.